Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02983461 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Use of Sildenafil for Treatment of Urinary Incontinence

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion pushed from Jul 2027 to Jul 2028v16
  2. Study completion date: Jul 2025 to Jul 2027v15
  3. Study completion date: Mar 2024 to Jul 2025v14
  4. Re-verified, no change to tracked fieldsv13
  5. Study completion date: Mar 2022 to Mar 2024v12
Show 10 earlier versionsHide 10 earlier versions
  1. Primary completion date changed from estimate of Mar 2021 to Mar 1, 2020
    • Study completion date: Mar 2021 to Mar 2022
    v11
  2. Primary and study completion dates: Mar 2020 to Mar 2021
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v10
  3. Primary and study completion dates: Mar 2019 to Mar 2020v9
  4. Re-verified, no change to tracked fieldsv8
  5. Interventions: Placebo Oral Tablet (Drug), Sildenafil (Drug) to Placebo (Drug), Sildenafil (Drug)v7
  6. Re-verified, no change to tracked fieldsv6
  7. Eligibility criteria expanded, about 29 wordsv5
  8. Start date changed from estimate of Feb 2017 to Mar 10, 2017v4
  9. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v3
  10. Start date: Jan 2017 to Feb 2017v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The investigators goal is to develop medical treatments for stress/mixed urinary incontinence. Sildenafil has been shown to improve blood flow as well as muscle mass and strength and to decrease muscle fatigue. The investigators believe that it will improve muscular atrophy in the pelvic floor, thus improving symptoms of urinary incontinence related to pelvic floor dysfunction.
Trial Details
NCT Number NCT02983461
Lead Sponsor The University of Texas Medical Branch, Galveston
Conditions
(from sponsor)		 Urinary Incontinence
Related terms Urinary Incontinence
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov